Nimesulide (Nise) influence on blood serum prostaglandin E2 concentration and cardiovascular system function in patients with rheumatoid arthritis
https://doi.org/10.14412/1995-4484-2009-584
Abstract
Objective. The purpose of the current study was to investigate nimesulide effects on prostaglandin E 2 concentration in blood serum and some parameters of the cardiovascular system in pts with RA during a 6-month period. Materials and methods. 40 RA pts were studied, 20 of them took 200 mg of nimesulide per day (24 hours) in combination with low doses of metatrexate (7.5-10.0 mg per week). The pts were studied for 6 months. The content of E2 prostaglandin in blood serum was evaluated and estimated by means of the immuneenzymic method in 20 pts who took 200 mg of nimesulide per day (24 hours) in comparison with 20 pts who took 100 mg of sodium diclofenac per day. The cardiovascular system was evaluated and estimated by means of screening examinations and after the 6-month treatment period by means of 24-hour monitoring of arterial blood pressure, ECG-monitoring and echocardioscopy. Results. In case of the nimesulide treatment the above RA pts did not show reliable reduction of PGE- 2 in blood serum as compared with sodium dicofenac after a 5 day and the 6-month treatment. This showed the selective effect of nimesulide in relation to COX-2. As far as the parameters of the cardiovascular system are concerned, no negative dynamics were revealed at the background of nimesulide treatment . It was revealed that nimesulide is quite effective and has good tolerance.
References
1. <div><p>Каратеев А.Е., Каратеев Д.Е., Лучихина Е.Л. Эффективность и безопасность монотерапии высокими дозами НПВП при раннем артрите (открытое рандомизированное контролируемое 4-недельно исследование эффективности высоких и среднетерапевтических доз нимесулида и диклофенака при раннем артрите: предварительные данные). Русск. мед. жур., 2006, 25, 14, 3-7</p><p>Кудаева Ф.М., Елисеев М.С., Барскова В.Г. Сравнение скорости наступления анальгетического и противовоспалительного эффектов различных форм нимесулида и диклофенака натрия при подагрическом артрите. Тер. архив, 2007, 5, 35–40</p><p>Лазебник Л.Б., Дроздов В.Н., Коломиец Е.В. Сравнительная эффективность и безопасность применения кетопрофена, лорноксикама, нимесулида и целекоксиба у больных остеоартрозом. Русск. мед. жур., 2004, 14, 12, 844-7</p><p>Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр, проект). Жур. сердечн. недостаточн., 2006, 2 ,36, 52–78</p><p>Ребров А.П., Инамова О.В. Предпосылки развития эндотелиальной дисфункции при ревматоидном артрите. Тер. архив, 2004, 5, 79-85</p><p>Сидорова Н.В., Белькин Ю.А. Мониторирование артериального давления. Рук. для врачей. М., Медицина, 2002, 37</p><p>Симоненко В.Б., Цоколов А.В., Фисун А.Я. Функциональная диагностика. Рук. для врачей. М., Медицина, 2005, 304</p><p>Чичасова Н.В., Имаметдинова Г.Р., Насонов Е.Л. Возможность применения селективных ингибиторов цог-2 у больных с заболеваниями суставов и сопутствующей артериальной гипертензией. Научно-практич. ревматол., 2004, 2, 1-4</p><p>Blain H, Boileau C, Lapicque F. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin. Pharmacol., 2002, 53, 3, 255-65</p><p>Gerritsen ME, Niedbala MJ, Szczepanski A. Cytokine activation of human macro- and microvessel-derived endothelial cells. Blood Cells, 1993, 19, 2, 325-39</p><p>Hills W. Areas of emerging interest in analgesia: cardiovascular complications. Amer. J. Ther., 2002, 9, 259-69</p><p>Khanapure SP, Garvey DS, Janero DR. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr. Top. Med. Chem., 2007, 7, 3, 311-40</p><p>Rincon ID, Williams K, Stern MP et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum., 2001, 44, 2737-45</p><p>Schwartz JI, Dallob AL, Larson PJ. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J. Clin. Pharmacol., 2008, 48, 6, 745-54</p><p>Seriolo В., Sulli A., Burroni A., Cutolo M. Rheumatoid arthritis and atherosclerosis. Reumatismo, 2003, 55, 140-46</p><p>Warner TD, Giuliano F, Vojnovic. Nonsteroid drug selektivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA., 1999, 96, 13, 7563-7568</p><p>Xiao CY, Yuhki K, Hara A. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation, 2004, 109, 20,2462-8</p><p>Yamada M, Niki H, Yamashita M. Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. J. Pharmacol. Exp. Ther., 1997, 281, 2, 1005-12</p></div><br />
Review
For citations:
Nemtsov B.F., Shilkina I.A. Nimesulide (Nise) influence on blood serum prostaglandin E2 concentration and cardiovascular system function in patients with rheumatoid arthritis. Rheumatology Science and Practice. 2009;47(5):18-23. (In Russ.) https://doi.org/10.14412/1995-4484-2009-584
Views:
1614
Email this article 